Literature DB >> 29261301

Redox-Inactive Peptide Disrupting Trx1-Ask1 Interaction for Selective Activation of Stress Signaling.

Dilini N Kekulandara1, Shima Nagi1, Hyosuk Seo1, Christine S Chow1, Young-Hoon Ahn1.   

Abstract

Thioredoxin 1 (Trx1) and glutaredoxin 1 (Grx1) are two ubiquitous redox enzymes that are central for redox homeostasis but also are implicated in many other processes, including stress sensing, inflammation, and apoptosis. In addition to their enzymatic redox activity, a growing body of evidence shows that Trx1 and Grx1 play regulatory roles via protein-protein interactions with specific proteins, including Ask1. The currently available inhibitors of Trx1 and Grx1 are thiol-reactive electrophiles or disulfides that may suffer from low selectivity because of their thiol reactivity. In this report, we used a phage peptide library to identify a 7-mer peptide, 2GTP1, that binds to both Trx1 and Grx1. We further showed that a cell-permeable derivative of 2GTP1, TAT-2GTP1, disrupts the Trx1-Ask1 interaction, which induces Ask1 phosphorylation with subsequent activation of JNK, stabilization of p53, and reduced viability of cancer cells. Notably, as opposed to a disulfide-derived Trx1 inhibitor (PX-12), TAT-2GTP1 was selective for activating the Ask1 pathway without affecting other stress signaling pathways, such as endoplasmic reticulum stress and AMPK activation. Overall, 2GTP1 will serve as a useful probe for investigating protein interactions of Trx1.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29261301      PMCID: PMC5856478          DOI: 10.1021/acs.biochem.7b01083

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  67 in total

1.  Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta.

Authors:  Niki L Reynaert; Albert van der Vliet; Amy S Guala; Toby McGovern; Milena Hristova; Cristen Pantano; Nicholas H Heintz; John Heim; Ye-Shih Ho; Dwight E Matthews; Emiel F M Wouters; Yvonne M W Janssen-Heininger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

2.  Cysteine residues mediate high-affinity binding of thioredoxin to ASK1.

Authors:  Salome Kylarova; Dalibor Kosek; Olivia Petrvalska; Katarina Psenakova; Petr Man; Jaroslav Vecer; Petr Herman; Veronika Obsilova; Tomas Obsil
Journal:  FEBS J       Date:  2016-09-18       Impact factor: 5.542

3.  Evaluation of a dithiocarbamate derivative as an inhibitor of human glutaredoxin-1.

Authors:  Satya S Sadhu; Eduardo Callegari; Yong Zhao; Xiangming Guan; Teresa Seefeldt
Journal:  J Enzyme Inhib Med Chem       Date:  2012-02-03       Impact factor: 5.051

4.  Hot-spot mutants of p53 core domain evince characteristic local structural changes.

Authors:  K B Wong; B S DeDecker; S M Freund; M R Proctor; M Bycroft; A R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Thioredoxin and TRAF family proteins regulate reactive oxygen species-dependent activation of ASK1 through reciprocal modulation of the N-terminal homophilic interaction of ASK1.

Authors:  Go Fujino; Takuya Noguchi; Atsushi Matsuzawa; Shota Yamauchi; Masao Saitoh; Kohsuke Takeda; Hidenori Ichijo
Journal:  Mol Cell Biol       Date:  2007-08-27       Impact factor: 4.272

Review 6.  Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling.

Authors:  Eva-Maria Hanschmann; José Rodrigo Godoy; Carsten Berndt; Christoph Hudemann; Christopher Horst Lillig
Journal:  Antioxid Redox Signal       Date:  2013-03-28       Impact factor: 8.401

Review 7.  Thioredoxin signaling as a target for cancer therapy.

Authors:  Garth Powis; D Lynn Kirkpatrick
Journal:  Curr Opin Pharmacol       Date:  2007-07-03       Impact factor: 5.547

8.  The role of thioredoxin-1 in suppression of endoplasmic reticulum stress in Parkinson disease.

Authors:  Xian-Si Zeng; Jin-Jing Jia; Yongwon Kwon; Sheng-Dong Wang; Jie Bai
Journal:  Free Radic Biol Med       Date:  2013-10-17       Impact factor: 7.376

9.  Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.

Authors:  Changping Li; Michael A Thompson; Archito T Tamayo; Zhuang Zuo; John Lee; Francisco Vega; Richard J Ford; Lan V Pham
Journal:  Oncotarget       Date:  2012-03

10.  High thioredoxin-1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab.

Authors:  Katharina Heim; Benjamin Dälken; Stefanie Faust; Faiza Rharbaoui; Andre Engling; Holger Wallmeier; Theodor Dingermann; Heinfried H Radeke; Jörg Schüttrumpf; Marcus Gutscher
Journal:  Clin Transl Immunology       Date:  2016-12-23
View more
  4 in total

1.  Agomelatine rescues lipopolysaccharide-induced neural injury and depression-like behaviors via suppression of the Gαi-2-PKA-ASK1 signaling pathway.

Authors:  Tian Lan; Yuhan Wu; Yulei Zhang; Shuhan Li; Zhanpeng Zhu; Liyan Wang; Xueqin Mao; Ye Li; Cuiqin Fan; Wenjing Wang; Shu Yan Yu
Journal:  J Neuroinflammation       Date:  2022-05-24       Impact factor: 9.587

2.  Phosphoproteomics identify arachidonic-acid-regulated signal transduction pathways modulating macrophage functions with implications for ovarian cancer.

Authors:  Raimund Dietze; Mohamad K Hammoud; María Gómez-Serrano; Annika Unger; Tim Bieringer; Florian Finkernagel; Anna M Sokol; Andrea Nist; Thorsten Stiewe; Silke Reinartz; Viviane Ponath; Christian Preußer; Elke Pogge von Strandmann; Sabine Müller-Brüsselbach; Johannes Graumann; Rolf Müller
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 3.  The Thioredoxin System of Mammalian Cells and Its Modulators.

Authors:  Aseel Ali Hasan; Elena Kalinina; Victor Tatarskiy; Alexander Shtil
Journal:  Biomedicines       Date:  2022-07-21

Review 4.  ASK1 inhibition: a therapeutic strategy with multi-system benefits.

Authors:  Jacqueline M Ogier; Bryony A Nayagam; Paul J Lockhart
Journal:  J Mol Med (Berl)       Date:  2020-02-14       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.